Open access
2026
The design, synthesis and antitumour evaluation of BCL3 inhibitors targeting advanced colorectal and breast cancers
The B-cell lymphoma 3 protein (BCL3) is a transcriptional facilitator protein and anti-cancer drug target driving intracellular cancer signalling pathways including NF-κB (advanced breast) and Wnt-β-catenin (colorectal). BCL3 governs pro-oncogenic processes such as tumour initiation, metastasis, and therapy resistance....
A. D. Westwell, D. Ružić, T. Elstow et al.
· Zbornik radova · 0 citations